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Abstract
Acute heart failure (AHF) is a common and serious condition that contributes
to about 5% of all emergency hospital admissions in Europe and the USA.
Here, we present the recommendations from structured discussions among
an author group of AHF experts in 2013.
The epidemiology of AHF and current practices in diagnosis, treatment, and
long-term care for patients with AHF in Europe and the USA are examined.
Available evidence indicates variation in the quality of care across hospitals
and regions. Challenges include the need for rapid diagnosis and treatment,
the heterogeneity of precipitating factors, and the typical repeated episodes
of decompensation requiring admission to hospital for stabilization.
In hospital, care should involve input from an expert in AHF and auditing to
ensure that guidelines and protocols for treatment are implemented for all
patients. A smooth transition to follow-up care is vital. Patient education
programmes could have a dramatic effect on improving outcomes. Informa-
tion technology should allow, where appropriate, patient telemonitoring and
sharing of medical records. Where needed, access to end-of-life care and
support for all patients, families, and caregivers should form part of a
high-quality service.
Eight evidence-based consensus policy recommendations are identified by the
author group: optimize patient care transitions, improve patient education and
support, provide equity of care for all patients, appoint experts to lead AHF
care across disciplines, stimulate research into new therapies, develop and
implement better measures of care quality, improve end-of-life care, and
promote heart failure prevention.
Keywords Acute disease; Heart failure/diagnosis; Heart failure/therapy; Humans;
Patient care team; Patient-centred care
Executive summary
For millions of people throughout the world, acute heart failure is a life-
threatening medical emergency, and it is one of the most common reasons
for admission to hospital. One in 10 patients with acute heart failure dies in
hospital, and one in three dies within the year following an episode. Despite
advances in long-term care, no new treatments for acute heart failure have
emerged during the past two decades. Demands on services and the need for
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treatment will rise as the number of people with heart
failure increases in our ageing populations.
It is time to address the needs of patients with acute
heart failure by means of clear policy initiatives and ratio-
nal redesign of patient management pathways and
healthcare provision. Change at the policy level has the
power to save lives and the potential for more efficient
use of resources, as this report shows.
The symptoms of acute heart failure are distinct from
those of a heart attack. Breathlessness, fatigue, and swell-
ing of the lower legs or ankles are surprisingly often not
recognized by patients and clinicians as the life-threatening
symptoms of declining heart function. The underlying
causes of acute heart failure are varied, and patients exhibit
different patterns and severity of symptoms. This means
that many patients experience complex transitions be-
tween different healthcare providers and facilities.
For patients who survive a first episode of acute heart
failure, modern evidence-based treatments can reduce the
risk of another episode but require careful management.
These potentially life-saving treatments are often not pre-
scribed appropriately on discharge from hospital, and about
25% of patients are readmitted within a month. Good
management reduces readmission rates, improves survival
rates, uses resources efficiently, and may reduce costs.
It is time to ensure that excellent care becomes routine.
We know that patients with heart failure are more
likely to survive when treated and followed up by special-
ist cardiology units. Many patients with heart failure have
other medical conditions, requiring treatment by a variety
of specialists. Ensuring the best care in hospital involves a
multidisciplinary team, supported and often led by an
expert in heart failure. Excellent care involves developing
and implementing guidelines and protocols for treatment
and introducing a system of audits to ensure they are
properly applied.
When discharged from hospital, patients need a smooth
and swift transition to follow-up care, as well as the right
medications at the right doses. In addition, they need
support and education to help them to engage actively
in their own care, take the medications prescribed, and
ensure that any future deterioration is identified quickly.
The level of knowledge about heart failure is low among
the general public, and even among patients. Surveys
show that many patients who have had acute heart failure
remain unable to recognize warning symptoms of future
episodes. Education programmes directed at patients
and the public could have a dramatic effect on improving
outcomes for patients.
By designing rational, evidence-based healthcare
systems appropriate to each individual setting, the high
standards of acute heart failure care already achieved in
some hospitals and clinics could be made universal.
Emerging information technology could support existing
measures, by allowing remote monitoring of patients out-
side hospital and sharing of medical records among
healthcare professionals. Where needed, access to end-
of-life care and support for all patients, families, and care-
givers should form part of a revitalized service.
Continuing clinical research is needed to develop new
medications and devices for acute heart failure in order
to reduce death rates and improve patients’ quality of life.
However, it would be unwise merely to wait for new treat-
ments. Much-needed changes in management, protocols,
and procedures can and should be initiated now.
Policy recommendations
• Acute heart failure is a common and deadly disease
that contributes to about 5% of all emergency hospital
admissions in Europe and the USA. Numbers of admis-
sions for heart failure are growing as its prevalence
increases.
• Most patients with heart failure are over 75years of
age, and approximately half of these will die within a
year of hospital admission. Of patients aged under
75years, about one in five will die within a year of
admission.
• We therefore urge policy-makers at international, na-
tional, regional, and local levels to act on the following
recommendations.
1. Optimize care transitions
Better integration of hospital care, community care,
and the emergency services will improve patient
outcomes and enable more efficient use of resources.
Currently, hospital admission and discharge planning
are often poorly organized and inconsistently imple-
mented, indicating a need for closer relationships
among all those involved in patient care.
2. Improve patient education and support
Better education and support for individuals with
heart failure, and their families and caregivers, are
essential to improve outcomes and patients’ experi-
ence of care. Patients frequently lack the knowledge,
confidence, and support to be actively involved in
their own care, and their adherence to measures
important for long-term health is often poor.
3. Provide equity of care for all patients
All patients should have timely access to an appro-
priate range of diagnostic procedures, therapies, and
long-term follow-up care. Currently, the quality of
care varies considerably among hospitals, and across
regions and countries.
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4. Appoint experts to lead heart failure care across
disciplines
A multidisciplinary team led by a heart failure expert
should oversee the care of patients with acute heart
failure and the development of protocols, training,
and local auditing to make excellent care the norm.
5. Stimulate research into new therapies
Increased funding is needed for research into new and
more effective therapies, medical devices, and care
strategies for acute heart failure. New approaches
are urgently required to address unmet needs.
6. Develop and implement better measures of care
quality
Performance measures based on robust, evidence-
based clinical recommendations should be developed
and used to improve the quality of care for patients
with acute heart failure. Current performance mea-
sures are variable and lack an evidence base, and their
use may have unintended consequences.
7. Improve end-of-life care
Effective approaches to palliative and end-of-life care,
addressing emotional and physical well-being, need to
be made an integral part of the care of patients with
heart failure, both in hospital and in the community.
8. Promote acute heart failure prevention
Country-wide efforts to decrease risk factors for heart
failure, including high blood pressure and coronary
artery disease, should be intensified. Once heart
failure develops, progression of the disease should be
prevented or slowed by ensuring that appropriate
evidence-based care is implemented promptly.
Introduction and aims
This report summarizes the evidence and consensus
findings from structured discussions among the author
group, comprising clinicians and researchers, an ad-
vanced practice nurse, and the head of a patient action
group, all with expertise and experience in the field of
heart failure. The report presents the evidence base for
eight policy recommendations aimed at improving care
and preventing deaths of patients with acute heart failure.
Heart failure is common, affecting around 1–2% of
adults in developed countries.1 It occurs predominantly
in older individuals, with more than 10% of those aged
75years or above affected.2 In all, about one in five of
us will develop heart failure over the course of our
lives1
Most patients experience episodes of acute heart
failure—sudden worsening of the symptoms and signs
of deteriorating heart function. Acute heart failure is
often a life-threatening event requiring urgent medical
attention and can mark a transition to a more debili-
tating phase of the disease. Up to 10% of patients with
acute heart failure die in hospital, and 20–40% die
within a year, while 20–25% are back in hospital within
a month.3–10
Patients’ progression from an initial diagnosis of acute
heart failure to the terminal stages of the disease will
place changing demands on their families and caregivers,
and on healthcare services. The acute episodes that
typically punctuate chronic disease make increasing de-
mands on healthcare resources. Finally, in the terminal
stages of heart failure, patients may need end-of-life care.
The number of people with heart failure is predicted to
increase substantially over the coming decades, through a
combination of an ageing population and increased sur-
vival of patients with heart problems, thanks to improved
treatments.11,12 Greater numbers of patients will increase
the pressure on healthcare resources in the future. Hospi-
talizations for heart failure are predicted to rise substan-
tially,13 increasing the projected costs of treatment.14
There is therefore a need to seize the opportunities
highlighted in this report in order to use existing re-
sources more efficiently.
This report examines the care of patients with acute
heart failure in Europe and the USA and makes
evidence-based recommendations for policy change. In
presenting the evidence, the following sections will
• reveal the impact of acute heart failure on patients, on
their families and caregivers, and on society (section
Acute Heart Failure and the Burden of Disease)
• describe the complex healthcare trajectories followed
by patients with acute heart failure (section Clinical
Course of Acute Heart Failure)
• demonstrate the need for improved diagnosis and rec-
ognition of acute heart failure (section Diagnosis of
Acute Heart Failure)
• show why continued research into new and more effec-
tive medications and devices is necessary (section
Treatment of Acute Heart Failure)
• highlight the variation in care of patients with the
disease and present ways of providing better care to
all (section Treatment of Acute Heart Failure)
• explain the importance of patients’ transition to long-
term care and the role of disease management (section
Transition from Hospital to Community Care)
• set out practical approaches for improving the care of
patients with acute heart failure for policy-makers
and other stakeholders (section Recommendations for
Wider Implementation).
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Acute heart failure and the burden of
disease
Key points
What is acute heart failure?
Acute heart failure is a life-threatening event requiring ur-
gent medical attention. It is characterized by breathless-
ness (dyspnoea) at rest or on exertion and worsening
fluid retention, apparent as lung congestion and/or swol-
len ankles and legs. Definitions of acute heart failure vary,
with the European Society of Cardiology (ESC) treatment
guidelines referring to the ‘rapid onset of, or change in,
symptoms’ of heart failure,15 whereas another definition
includes gradual changes.16 For large numbers of patients,
the sudden appearance or reappearance of heart failure
symptoms leads to an emergency room visit and
hospitalization.
A wide range of abnormalities in cardiac structure
or function can cause heart failure, including disorders
of the heart muscle, valves, and rhythm. This complex-
ity makes heart failure difficult to define precisely.
Definitions differ between the ESC, American College
of Cardiology Foundation (ACCF)/American Heart As-
sociation (AHA), and National Heart Foundation of
Australia treatment guidelines (Table 1), 15,17,18 while
the one provided by the Heart Failure Society of Amer-
ica (HFSA) is more extensive.19 Symptoms can also
vary considerably among patients and are not specific
to heart failure, so diagnosis can be challenging.15
Impact of heart failure on individuals
and society
Heart failure is a major health issue in society today,
because it is associated with ill health, death, and con-
sumption of healthcare resources. Heart failure affects
approximately 1–2% of adults in developed countries,
and prevalence increases markedly with age.11 Few
individuals under 50 years of age are diagnosed with
heart failure, whereas more than 10% of those aged
75years or above have the disease.2,20
In all, about one in five individuals will develop
heart failure at some point.1 The Framingham Heart
Study in the USA showed that the lifetime risk of de-
veloping heart failure was similar in men and women
and that it did not change with increasing age, being
around 20% at both 40 and 80 years of age.1
The number of patients with heart failure is predicted
to increase substantially over the coming decades,
through a combination of an ageing population, improve-
ments in treatment, and the survival of patients with
heart problems.11 In the USA, an estimated 3% of the
adult population—8.5 million people—will have heart
failure by 2030.14
Most patients with heart failure experience acute
episodes (also known as acute decompensation) over the
course of the disease, which typically result in visits to
the emergency department and hospital admission. Hospi-
talization data for heart failure therefore reflect the high
healthcare activity associated with acute episodes.
• Acute heart failure is serious, requires urgent atten-
tion, and usually results in admission to hospital.
• Acute heart failure is characterized by breathlessness
at rest or on exertion and by fluid retention, resulting
in swollen ankles and legs.
• Heart failure is common—one in five people will
develop it at some point—and it affects mainly older
people, so patient numbers are increasing as the popu-
lation ages.
• Heart failure can lead to social isolation, anxiety,
and depression, as symptoms make patients less
able to participate in work and in social and leisure
activities.
• Management of acute heart failure makes extensive
demands on healthcare resources, with many patients
requiring repeated hospitalization.
• Despite continuing improvements, many patients with
acute heart failure die in hospital or soon after leaving
hospital, and most die within 5 years.
Table 1 Three of several accepted definitions of heart failure
Treatment guideline Heart failure definition
ESC15 ‘…an abnormality of cardiac
structure or function leading
to failure of the heart to deliver
oxygen at a rate commensurate
with the requirements of the
metabolizing tissues, despite
normal filling pressures (or only
at the expense of increased
filling pressures).’
ACCF/AHA17 ‘…a complex clinical syndrome
that results from any structural or
functional impairment of ventricular
filling or ejection of blood.’
NHFA18 ‘…a complex clinical syndrome with
typical symptoms (e.g. dyspnoea,
fatigue) that can occur at rest or on
effort, and is characterised by objective
evidence of an underlying structural
abnormality or cardiac dysfunction that
impairs the ability of the ventricle to
fill with or eject blood (particularly during
physical activity).’
ACCF, American College of Cardiology Foundation; AHA, American
Heart Association; ESC, European Society of Cardiology; NHFA, Na-
tional Heart Foundation of Australia.
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High hospitalization and death rates
Hospitalization and death rate data for patients with
heart failure are available from several different sources,
including government health service statistics, healthcare
databases (such as Medicare in the USA), patient registry
data and studies in patients hospitalized with acute heart
failure. The range of data sources can mean that results
are not directly comparable across countries.
Hospitalization
The high numbers of hospitalizations for heart failure
place a substantial burden on healthcare systems.
Health service data for a number of European countries
show that hospitalizations with a primary diagnosis of
heart failure generally account for 1–2% of all hospital
admissions, while in the USA, they comprise about 3%
(Figure 1).21–31 In England, the proportion of hospital
admissions with a primary diagnosis of heart failure
was low (0.4%), but hospitalizations with any mention
of heart failure occurred in approximately 2.6% of all
cases.
Hospital discharge data may underestimate the extent
of heart failure, partly because it can coexist with other
conditions and might not therefore be recognized. For
example, an analysis in the UK showed that heart failure
was present but not recorded in a substantial proportion
of patients with a discharge diagnosis of atrial fibrillation,
a common co-morbidity of heart failure.32
Hospitalizations due to heart failure have increased
over the past decade in many European countries
(Table 2).22–28,33 A particularly large rise in admissions
has been observed in Germany (40% between 2000 and
2007), where heart failure is now the most common rea-
son for hospitalization.24 Data from England showed that
hospitalizations with any mention of heart failure have
increased by 57% since 2006,34 although admissions with
a primary diagnosis of heart failure have declined over
10 years.22 In the USA, Medicare data revealed a reduc-
tion in hospitalizations with a principal diagnosis of heart
failure33 whereas US National Hospital Discharge Survey
data indicated that the numbers of hospitalizations in
2000 and in 2010 were similar.35
The increasing prevalence of heart failure with age
means that the elderly make up a high proportion of
patients hospitalized for heart failure. In the USA in
2010, there were about one million hospitalizations
with heart failure as the principal diagnosis; patients
aged 65 years and over comprised 71% of these admis-
sions, while those aged 85 years and over accounted for
25%.35 Data from several European countries show that
more than half of hospitalizations for heart failure oc-
cur in patients aged 80 years or above.26,28,29 Overall,
in developed countries, heart failure is the most
Figure 1 Hospitalizations for heart failure in Europe and the USA. aData supplied by regional health system representatives in Poland.
HF (1°/2°), number of hospitalizations for heart failure as primary/secondary diagnosis; HF (any), number of hospitalizations for
heart failure as any diagnosis; HF/total, heart failure hospitalizations as a proportion of all hospitalizations; LoS, average length of
hospital stay; total, total number of hospitalizations. All data shown include planned admissions.
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common cause of hospitalization in patients aged over
65 years.36
Heart failure also accounts for a high proportion of
emergency department visits. Acute heart failure
accounted for 10.5 million visits or 2.9% of all emergency
department visits by patients aged 40 years or over in the
USA between 1992 and 2001.37 Almost 75% of these visits
resulted in hospitalization. In the UK, heart failure makes
up 5% of all emergency hospital admissions.13
Heart failure is associated with an even greater usage of
hospital resources than heart attack [acute myocardial in-
farction (AMI)]. In the USA, there were 982000 hospital
discharges with an initial diagnosis of heart failure in
2007, compared with 577000 for heart attack.30 Hospital
data for England for 2011/2012 showed more hospital ad-
missions with a primary diagnosis of heart failure (61130)
than those of AMI (50708) and a longer average length of
stay for heart failure (7 days) than for AMI (4days).22
Length of hospital stay
Length of hospitalization for heart failure is typically be-
tween 5 and 10days, with longer stays generally reported
in Europe than in the USA. Longer stays may benefit some
patients. Findings are consistent between health service
data (Figure 1) and data from patient registries and other
studies (Figure 2).3,5,7,9,10,23,38–45
The average length of a hospital stay has decreased by
1–2days in European countries over the past
10 years.22,23,27,28 In the USA, the average length of stay
decreased from 5.6days in 2001 to 5.3days in 2009.31
However, the average length of stay tends to increase with
patient age. In Sweden, it was 5.2days for patients aged
60–64years comparedwith 7.2days for those aged 85years
and above;28 in England, it was 5days for those under
65years old and 9days for those aged over 85years.22
Hospital readmissions
Rehospitalization is common among patients with
acute heart failure following their initial discharge
(Table 3).4,8,10,38,46–52 The majority of readmissions
are related to cardiovascular disease,8,46,47,50 with re-
currence of heart failure the most common single rea-
son, accounting for about 30% of all cases.4,6,38,46,49,51
In European studies, reported rehospitalization rates
range from 24% at 12weeks10 to 44% at 1 year after dis-
charge.4 In the USA, 30day readmission rates were about
20–25%;8,49,51 however, readmission rates of 60–67%
have been reported with longer follow-up.8,38,50 An anal-
ysis of Veterans Affairs (VA) healthcare data between
2002 and 2006 showed an increase in 30day rehospitali-
zation for heart failure and improved survival (in hospital
and at 30days and 1 year) over this period.52 This analysis
suggests that the timely post-discharge visits used by the
VA system accompanied by early rehospitalization for
heart failure (when needed) are associated with improved
patient outcomes. Similar systems are in use in other
countries or regions.
Short-term survival rates
Death rates remain high for patients hospitalized with
heart failure, both in hospital and during follow-up.
In-hospital death rates are age related and typi-
cally range from 4% to 10% for patients with acute
heart failure in database and registry studies
(Figure 3),3,4,9,10,33,40,42–46,48,50,52,53 although higher
rates have been observed in some analyses.54,55 Short-
term survival is also poor, with 1 year death rates typi-
cally between 20% and 40% (Figure 3).
Some improvements in short-term and in-hospital
death rates have been observed in recent years.7,33,50,56,57
In an analysis of over 6.5 million heart failure hospitaliza-
tions in the USA, the unadjusted in-hospital death rate fell
from 8.5% in 1993 to 4.3% in 2006, and the 30day death
rate decreased from 12.8% to 10.7% over the same
period.7 Another Medicare analysis also reported a
decreased in-hospital death rate, from 5.1% in 2001 to
4.2% in 2005, although 180day and 1 year all-cause
death rates remained fairly constant at approximately
Table 2 Trends in hospitalizations for heart failure
Country
Percentage change in number
of hospitalizations Time period Reference
England 13.1 2001–02 to 2011–12 HSCIC22
Francea 14.4 2002 to 2008 Pérel et al.23
Germany 39.8 2000 to 2007 Neumann et al.24
Netherlands 21.0 2000 to 2010 Statistics Netherlands25
Norway 2.4 1999 to 2008 Statistics Norway26
Spain 22.3 2000 to 2011 Sistema Nacional de Salud27
Sweden 11.4 2001 to 2011 Socialstyrelsen28
USA (Medicare) 19.3 1999–2000 to 2007–08 Chen et al.33
Data based on total number of hospital admissions (emergency and planned) for a primary diagnosis of heart failure (except for France).
HSCIC, Health and Social Care Information Centre.
aPrimary diagnosis or secondary diagnosis with a primary diagnosis of either hypertensive heart disease or heart and renal disease with
heart failure or pulmonary oedema or chronic passive congestion of liver.
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26% and 37%, respectively.50 A reduction in the 1 year
death rate from 31.7% in 1999 to 29.6% in 2008 was
reported in an analysis of data from 55 million Medicare
patients.33
Long-term survival rates
Despite some ongoing improvement, long-term survival
of patients after an episode of acute heart failure also
remains poor, with reported 5 year death rates of
around 70% (Figure 4).3,9,58–61 A population study in
Scotland showed improvements in patients’ 1 year
and 5 year survival rates between 1983 and 2004 fol-
lowing their first hospitalization for heart failure, but
the 5 year death rate was still about 65% at the end
of this period.60 In a community-based study in the
USA, the 5 year death rate improved from 57% for pa-
tients newly diagnosed with heart failure in 1979–84
to 48% for those diagnosed in 1996–2000.61 In another
community-wide survey of acute heart failure, 2 year
and 5 year post-discharge death rates improved for
patients hospitalized in 2004 (45.3% and 70.5%,
respectively) compared with those admitted in 1995
(57.4% and 80.3%, respectively).9
Economic costs of heart failure
treatment
As a result of the high level of hospital activity, the costs of
heart failure treatment to society are substantial, account-
ing for approximately 1–2% of direct healthcare expendi-
ture in Western industrialized countries.24 In Germany,
the total direct treatment costs for heart failure were
€2.9bn in 2006, of which inpatient hospital care made
up 60%.24
In the USA, overall costs of heart failure in 2010 have
been estimated at $39.2bn, or about 2% of the healthcare
Figure 2 Length of hospital stay in acute heart failure studies. Length of stay values are means in US studies and medians in European
studies. aData for 24 individual countries also reported. ADHERE, Acute Decompensated Heart Failure National Registry; EHFS,
EuroHeart Failure Surveys; ESC-HF, European Society of Cardiology–Heart Failure; FINN-AKVA, Finnish Acute Heart Failure Study;
IN-HF, Italian Registry on Heart Failure; NDCHealth, National Data Corporation Health; NICOR, National Institute for Cardiovascular
Outcomes Research; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure;
OFICA, Observatoire Français de l’Insuffisance Cardiaque Aiguë.
Table 3 High hospital readmission rates in acute heart failure
studies
Study Country/region Rehospitalization rate (%)
Medicare49 USA 30-day 24.8
Medicare51 USA 30-day 26.9
VA health
care system52
USA 30-day 22.5
ADHERE8 USA 30-day 22.1
1-year 65.8
Medicare50 USA 30-day 22.7
1-year 67.0
Medicare38 USA 6–9-month 60
EHFS I10 Europe 12-week 24.2
ESC-HF Pilot4 Europe 1-yeara 43.9
EAHFE48 Spain 1-year 27.2
CCU47 Italy 6-month 38.1
IN-HF Outcome46 Italy 1-year 30.7
ADHERE, Acute Decompensated Heart Failure National Registry;
CCU, cardiac care unit; EAHFE, Epidemiology Acute Heart Failure
Emergency; EHFS, EuroHeart Failure Surveys; ESC-HF, European
Society of Cardiology–Heart Failure; IN-HF, Italian Registry on Heart
Failure; VA, Veterans Affairs.
aData for other time periods also reported.
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budget,62 although estimates vary.14 Hospitalization com-
prised approximately 80% of direct treatment costs for
heart failure in the USA.14 In an analysis of 1.1 million
Medicare patients in 2010, hospitalization costs for heart
failure were $91.9m, accounting for 3.1% of the total
expenditure.63
The use of healthcare resources is predicted to rise over
the coming decades as the number of patients with heart
failure increases. Hospitalizations for heart failure in the
UK are projected to rise by 50% over the next 25 years.13
while the costs of heart failure treatment in the USA are
predicted to more than double by 2030.14
Figure 3 High in-hospital and short-term death rates due to acute heart failure. ADHERE, Acute DecompensatedHeart Failure National
Registry; EAHFE, Epidemiology Acute Heart Failure Emergency; EHFS, EuroHeart Failure Surveys; ESC-HF, European Society of
Cardiology–Heart Failure; FINN-AKVA, Finnish Acute Heart Failure Study; IN-HF, Italian Registry on Heart Failure; NICOR, National
Institute for Cardiovascular Outcomes Research; NR, not reported; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment
in Hospitalized Patients with Heart Failure; OFICA, Observatoire Français de l’Insuffisance Cardiaque Aiguë; VA, Veterans Affairs.
Figure 4 High long-term death rates due to acute heart failure (UK and US data). a18month death rate. NICOR, National Institute for
Cardiovascular Outcomes Research.
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Impact of heart failure on patients and
their families
For patients, the physical limitations brought about by
shortness of breath, loss of energy, and fatigue associated
with heart failure affect work, social, and leisure activi-
ties.64 Patients commonly experience social isolation,
reporting limited ability to travel, socialize, or take part
in recreational activities.65
Psychological effects, including fear, anxiety, and
depression, are common among individuals with heart
failure.64 Furthermore, heart failure can have a marked
effect on personal relationships, with the increasing
reliance on others leading to feelings of guilt and frustra-
tion.65 In addition, family members often feel the burden
of caring for a patient with heart failure, and these
demands can have physical, emotional, and financial
effects on them.66
Clinical course of acute heart failure
Key points
What is the outlook for patients with
heart failure?
The clinical course of heart failure can vary consider-
ably. Patients may present following gradual or sudden
onset of typical symptoms—breathlessness, fatigue,
and/or swollen ankles and legs—with rapid deteriora-
tion being more common.67 After successful initial treat-
ment for acute heart failure, patients may enter a
plateau phase where heart function remains stable
(Figure 5). The length of this phase varies among indi-
viduals and can last several years. Over time, most
patients experience multiple episodes of acute heart
failure, which typically become longer and separated
by shorter intervals as the ability of the heart to recover
declines.67,68 These episodes are also referred to as
acute decompensation or acutely decompensated
chronic heart failure: the heart fails to maintain ade-
quate blood flow by adjusting its output in response to
demand. For some patients, however, the decline in
heart function follows a steeper path. Throughout its
course, patients with heart failure are at risk of
sudden death due to acute decompensation.67 Subse-
quent prognosis is generally poor for patients who are
resuscitated following one such episode.
Differences in outcomes between patients in the
acute and chronic phases of heart failure are apparent
from observational studies that enrolled both types of
patient. In the ESC–Heart Failure (ESC-HF) Pilot study,
death rates at 1 year were 7.2% in outpatients with
chronic heart failure and 17.2% for patients hospital-
ized with acute disease.4 In the Italian Registry on
Heart Failure Outcome study, 1 year death rates were
5.9% in patients with chronic heart failure and 24.0%
in those with acute heart failure.46 Hospitalization
rates in the year after enrolment were also lower for
those with chronic disease than those with acute
disease.4,46
For many individuals, underlying abnormalities of
cardiac function may be present for some time before
the appearance of heart failure symptoms.15 In popula-
tion studies, up to 21% of individuals showed changes
in measures of left ventricular function but no symp-
toms of heart failure (referred to as asymptomatic left
ventricular dysfunction).69–71 This was associated with
an increased risk of symptomatic heart failure and an
Figure 5 Typical progression of acute heart failure, showing a
range of clinical courses. A, good recovery after first episode
followed by stable period of variable length; B, first episode not
survived; C, poor recovery after first episode followed by deteri-
oration; D, ongoing deterioration with intermittent crises and
unpredictable death point.
• Symptoms and signs may worsen gradually or abruptly,
and the subsequent clinical course of heart failure can
vary considerably.
• As the disease progresses, episodes of acute heart
failure are likely to happen more often, and patients
become less likely to make a good recovery.
• High blood pressure, diabetes, kidney disease, obesity,
physical inactivity, excessive alcohol intake, and
smoking all increase the risk of developing heart
failure.19
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increased risk of death.71 These individuals are a key
target for approaches aimed at preventing the develop-
ment of heart failure, such as improving diet and exer-
cise, stopping smoking, and controlling high blood
pressure (see below).72
Patient perspective
…they [discharged me from hospital] after 6 days,
and I seemed to be okay. And then in 1998 the
symptoms they started again. And in 1999 I had a
bad attack, but I didn’t go to the hospital.… This last
time in March was probably the third time I was—my
wife said the fourth time—I was hospitalized for the
same symptoms.73
What goes wrong in patients with heart
failure?
Numerous cardiovascular abnormalities can lead to the
development of heart failure, although the functional
changes that underlie the disease are complex and incom-
pletely understood. These abnormalities result in a
number of physiological changes, including water and
sodium retention, constriction of blood vessels, and
increased heart function, that act to maintain blood flow.
However, prolonged activation of these compensatory
mechanisms leads to detrimental changes in the heart,
circulatory system, and other organs.74
The structural changes that occur in the failing heart
mean that functioning of the ventricles is impaired
(Figure 6).15,75,76 Initially, blood flow to the body is
usually maintained, but as the disease progresses, the
ability of the heart to supply blood to the tissues is
reduced. In addition, the changes to the heart and circula-
tion lead to the build-up of fluid in the lungs and tissues,
known as pulmonary and peripheral oedema, or conges-
tion. This results in the characteristic heart failure symp-
toms of breathlessness and swollen legs and ankles, and
patients can experience increases in body weight as a
result of fluid retention. Changes to skeletal muscle are
also seen in heart failure, contributing to fatigue and
patients’ limited ability to exercise.
Reducing the risk of developing heart
failure
Several factors have been identified that increase the risk
of individuals developing heart failure, including high
blood pressure, hyperlipidaemia (high levels of fat in the
blood), atherosclerosis, diabetes, obesity, physical in-
activity, kidney disease, excessive alcohol intake, and
smoking.19 Clinical trials have shown that treatment to
reduce blood pressure can reduce the risk of developing
heart failure. In the Hypertension in the Very Elderly
Trial, such medications reduced the risk of heart failure
by 72% compared with placebo in elderly patients
(≥80 years old) with high blood pressure.77 Drugs to treat
high blood pressure also significantly reduced the risk of
heart failure in individuals at high risk of cardiovascular
events in the Heart Outcomes Prevention Evaluation
trial.78 Identifying individuals at risk of heart failure and
managing these factors through treatment and/or behav-
ioural changes could help to prevent the development of
the disease.
A model predicting the 5 year risk of heart failure has
been developed, based on factors such as age, smoking
history, systolic blood pressure (SBP), heart rate, and
fasting glucose levels.79,80 This could prove useful in the
identification of high-risk patients by healthcare profes-
sionals, allowing prevention programmes to be targeted
at these individuals.
In addition, public education programmes about heart
failure are needed to highlight the seriousness of the dis-
ease, raise awareness of its signs and symptoms, and pro-
mote heart failure prevention messages such as smoking
cessation, healthy diet, and exercise. Only 3% of respon-
dents correctly identified heart failure from a description
of typical signs and symptoms (‘breathlessness, tiredness,
or swollen ankles’) in the Study of Heart Failure Aware-
ness and Perception in Europe survey of almost 8000 peo-
ple in nine European countries.81 In contrast, 28%
identified heart attack/angina, and 48% identified stroke
or its equivalent from a description. Moreover, only 29%
of respondents considered heart failure ‘a severe com-
plaint’ based on the description of signs and symptoms,
and 34% perceived it to be ‘a normal consequence of
getting older’.81
Essential steps in the care of patients
with acute heart failure
Optimal management of acute heart failure can be broken
down into three key stages:
• timely and accurate diagnosis of the disease;
• rapid treatment of patients in the acute failure setting;
and
• seamless transition to therapies, management strate-
gies, information, and support for patients in the
chronic phase of the disease.
Effective care is required at all three stages to achieve
the best possible outcomes. These three aspects of acute
heart failure management are discussed in the following
sections.
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Our evidence-based policy
recommendations
Improve patient education and support
Better education and support for individuals with
heart failure, and their families and caregivers, are
essential to improve outcomes and patients’ experi-
ence of care. Patients frequently lack the knowledge,
confidence, and support to be actively involved in
their own care, and their adherence to measures
important for long-term health is often poor (Recom-
mendation 2).
Figure 6 Systolic and diastolic heart failure. Systolic heart failure: Approximately half of patients with heart failure have left ventric-
ular systolic dysfunction, in which the ability of the left ventricle (LV) to contract and pump blood to the body is reduced. In the nor-
mal heart (A), about 50% of the blood in the LV is ejected into the aorta and the body as the chamber contracts; this is known as the
ejection fraction. In systolic heart failure (B), changes to the LV (enlargement of the chamber and impaired contractility) mean that a
much smaller proportion of the blood in the LV before contraction (typically <40%) is ejected. Systolic heart failure is therefore also
known as heart failure with reduced ejection fraction (HF-REF). The total amount of blood leaving the LV in HF-REF may be similar to
normal, as the enlarged LV contains more blood than in the normal heart. Diastolic heart failure: Impaired filling of the LV (diastolic
dysfunction) is the main factor underlying development of diastolic heart failure (C). Characteristic changes to the heart include
thickening of the left ventricular wall and enlargement of the left atrium. The proportion of blood ejected from the LV is normal
or near normal although the changes to the LV wall mean that the total volume of blood may be lower than normal and pressure in-
side the heart may be higher than normal. Diastolic heart failure is also known as heart failure with preserved ejection fraction (HF-
PEF). Compared with HF-REF, patients with HF-PEF are generally older, more frequently female, and most have a history of high
blood pressure.15,75 HF-PEF is becoming more common; however, there are currently few effective treatments for HF-PEF.76
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Promote acute heart failure prevention
Country-wide efforts to decrease risk factors for heart
failure, including high blood pressure and coronary
artery disease, should be intensified. Once heart fail-
ure develops, progression of the disease should be
prevented or slowed by ensuring that appropriate
evidence-based care is implemented promptly (Rec-
ommendation 8).
Diagnosis of acute heart failure
Key points
Importance of early and accurate
diagnosis
Timely and accurate diagnosis is the first step in the treat-
ment of patients with acute heart failure. However, acute
heart failure can be difficult to differentiate from other
conditions, because the symptoms are not specific to heart
failure and may vary widely among patients. Further-
more, poor awareness of the symptoms of acute heart fail-
ure often leads to a time lapse between the development
of symptoms and seeking medical attention, delaying di-
agnosis and treatment.
Education is a key factor in improving the early identi-
fication of episodes of acute heart failure, although ap-
proaches will differ for newly diagnosed patients and
those already being treated for heart failure. Many indi-
viduals who are newly diagnosed with heart failure have
a history of other conditions such as coronary heart
disease and hypertension. Educating such patients and
the healthcare professionals involved in their care about
the signs and symptoms of acute heart failure should
speed up the identification of new cases. For patients
already diagnosed with heart failure, symptom monitor-
ing by patients and their family and caregivers is impor-
tant for the early detection of acute episodes.
Challenges of acute heart failure
diagnosis for healthcare professionals
Diagnosis of acute heart failure relies on a combination of
clinical evaluation, patient history, electrocardiography,
cardiac imaging, and laboratory tests (Figure 7).15 The
main symptoms of heart failure are non-specific, so they
do not differentiate heart failure from other conditions
such as chronic obstructive pulmonary disease (COPD),
while other, more specific symptoms [such as orthopnoea
(breathlessness when lying flat)] are less common.15,19
Symptoms also vary among patients at presentation. In
a national audit of patients in the UK with heart failure,
30% had severe shortness of breath at admission, 40%
had breathlessness that limited activity, and 43% had
moderate or severe peripheral oedema.82
Patient history can prove a useful guide to diagnosis, as
approximately 65% of patients with acute heart failure
also have pre-existing chronic heart failure. Electrocardi-
ography and echocardiography are key diagnostic tests in
heart failure, providing information on heart rhythm and
conductance and on structural and functional changes.
The levels of the natriuretic peptides in the blood [such
as B-type natriuretic peptide (BNP) and N-terminal pro-
BNP], released by cardiac muscle cells in the ventricles in
response to excessive stretching, are useful in ruling out
heart failure. However, some primary care centres, hospi-
tals, or regions may not have the full range of diagnostic
tools at their disposal.
Diagnosis in the emergency room can prove a chal-
lenge, as symptoms may be life-threatening, so diagnosis
and treatment are usually carried out together. In this
situation, the key aims of therapy are to relieve symptoms,
stabilize blood pressure, maintain blood oxygen levels,
and prevent organ damage. This requires the following:
• rapid and accurate diagnosis of heart failure, diffe-
rentiating it from other possible conditions (e.g. COPD,
pulmonary embolism, and renal failure);
• identification of any precipitating factor (and its
treatment); and
• treatment of any potentially life-threatening conditions
(Figure 7).15
Many precipitating factors exist for acute heart failure,
and several may co-exist in a single patient (Figure 8).15,17,83
Heart attack, atrial fibrillation, and other heart rhythm and
valve disorders are all common triggers for acute decompen-
sation. Other non-cardiovascular factors, such as infections
and lack of treatment adherence, can also trigger its onset.
Cardiac and non-cardiac co-morbidities are another
source of variation in patients with acute heart failure. A
high proportion of patients have underlying coronary
heart disease and/or high blood pressure, while kidney
• Rapid identification of patients with acute heart failure
is the first step in providing effective care.
• Diagnosis can be challenging because symptoms vary
at presentation, and many different factors can cause
an episode of acute heart failure.
• Poor recognition of the signs and symptoms of acute
heart failure frequently leads to delays in diagnosis
and treatment.
• Education is needed to increase symptom awareness
among everyone involved in care—healthcare profes-
sionals, patients, their families, and their caregivers—
to ensure early diagnosis and treatment.
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Figure 7 European Society of Cardiology treatment guidelines: initial assessment of suspected acute heart failure. aFor example,
respiratory distress, confusion, SpO2< 90% or PaO2< 60mmHg (8.0 kPa).
bFor example, ventricular tachycardia, third-degree
atrioventricular block. cReduced peripheral and vital organ perfusion—patients often have cold skin and urine output ≤15mL/h
and/or disturbance of consciousness. dPercutaneous coronary revascularization (or thrombolysis) indicated if ST-segment elevation
or new left bundle branch block. eVasodilators should be used with great caution, and surgery should be considered for certain acute
mechanical complications (e.g. inter-ventricular septal rupture, mitral valve papillary muscle rupture). Reproduced by permission of
the European Society of Cardiology from McMurray et al.15 ECG, electrocardiogram; ESC, European Society of Cardiology; ETT,
endotracheal tube; IABP, intra-aortic balloon pump; NIV, non-invasive ventilation; NP, natriuretic peptide; PaO2, partial pressure of
oxygen in arterial blood; SpO2, oxygen saturation of arterial blood measured by pulse oximetry.
Figure 8 Overview of selected causes of acute heart failure. COPD, chronic obstructive pulmonary disease.
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disease, diabetes, and lung disease are also common. High
blood pressure (73%), coronary artery disease (57%),
and diabetes (44%) were the most common co-
morbidities in the Acute Decompensated Heart Failure
National Registry (ADHERE) study.53 In the EuroHeart
Failure Survey II, coronary heart disease and hyperten-
sion were each present in over 50% of patients, while
atrial fibrillation/flutter, diabetes, and valvular disease
were each present in at least 30%.43
Challenges of early symptom recognition for patients
The delay between a patient developing symptoms of
acute heart failure and seeking medical attention is often
considerable84 and is influenced by the speed of onset and
severity of the symptoms. The sudden development of
breathlessness (dyspnoea) from the accumulation of fluid
in the lungs (acute pulmonary oedema) usually prompts
rapid contact with medical services, whereas the gradual
appearance of swollen legs and ankles (peripheral
oedema) is more likely to be associated with delays in
seeking care.
The average delay between symptom onset and hospital
admission ranged from 2h to 7days in six studies
involving a mix of patients with and without a history of
heart failure.84 Breathlessness was among the symptoms
associated with short delays between symptom appear-
ance and hospital presentation in one study of patients
hospitalized for acute heart failure, whereas peripheral
oedema was linked to prolonged delays.85 Breathlessness
when lying flat (orthopnoea), oedema, and weight gain
have also been associated with long delays in hospital
admission.84 However, findings vary among studies and
can be contradictory, with breathlessness also associated
with increased delays in admission.
When the reasons for delay were examined, many
patients reported not realizing the importance of their
symptoms or not recognizing them as worsening heart
failure. The fact that the symptoms of heart failure often
develop gradually and appear non-threatening could
potentially explain the long delays in seeking care.
Surprisingly, more knowledge about heart failure was
associated with an increased delay in one Dutch study,
possibly as a result of patients attempting to manage the
symptoms themselves.86 It is therefore important that
care plans educate patients as to when it is appropriate
to seek medical attention.
Other factors such as depression may affect the
ability of patients to assess their symptoms effectively
and so delay care. Depressive symptoms are relatively
common in heart failure, affecting 20–40% of patients
with the disease.87 In the Coordinating Study Evaluat-
ing Outcomes of Advising and Counselling in Heart
Failure Patients, conducted in the Netherlands, average
delay between symptom onset and hospitalization
was significantly longer in patients with depressive
symptoms (120 h) than in those without such symp-
toms (54 h).87 Depressive symptoms independently
increased the risk of a delay of over 72 h by almost
50%.
The delay between the development of acute symptoms
and the seeking of medical attention has implications for
outcomes in patients with acute heart failure. Evidence
from ADHERE suggests that early treatments with vaso-
active agents (to control blood pressure) and intravenous
diuretics (to control fluid retention) are both associated
with lower risk of death during hospitalization than is
delayed treatment.88,89
Patient perspective
All of a sudden, I was developing sleep apnea or
wasn’t breathing right but [shrugged] it off until I
could hardly breathe at all the last few days. I did
ignore the original symptoms. The last day, I woke
up and couldn’t breathe well and told my kid to get
me to the hospital. I was unconscious when I got to
the hospital.73
Patient perspective
Oh, I’ve been having breathing problems for about 8
to 10 years, [but my physicians] were always blaming
it on my other health problems… The breathing, they
are contributing it to the toxicity of the chemicals,
because I was a painter and inhaled a lot, and
different things like that, and the soreness and
fatigue they were contributing it to the hepatitis C…
I’m a very difficult person to diagnose.73
Symptoms at presentation affect
subsequent management
For patients with shortness of breath at rest, presenta-
tion will typically be through the emergency depart-
ment with subsequent admission to inpatient care,
where treatment should involve input from a cardiolo-
gist. For patients with less severe symptoms of decom-
pensation, such as those who are comfortable at rest
but have shortness of breath on slight exertion, initial
presentation might be to their family physician or at
a heart failure clinic, as well as at the emergency de-
partment. The experience of these patients will be
more varied, depending on the severity of their illness
(Figure 9). They could be treated and sent home to re-
ceive long-term follow-up care, or care could involve
consultation with a cardiologist or an outpatient visit
for further assessment and treatment. However, there
is often an over-reliance on hospitalization because of
the limited availability of other care options such as
non-hospital facilities or heart failure clinics for
Improving care in acute heart failure 123
© 2015 Oxford PharmaGenesis Ltd ESC Heart Failure 2014; 1: 110–145
DOI: 10.1002/ehf2.12021
supervised daily care and treatment. A review of symp-
toms in patients hospitalized for acute heart failure
showed that at presentation, only 38% had severe
breathlessness at rest, while 62% were comfortable at
rest but breathless on slight exertion.90 This suggests
that the provision of more options for patient care
could help to reduce the number of hospitalizations
for heart failure.
Our evidence-based policy
recommendations
Optimize care transitions
Better integration of hospital care, community care, and
the emergency services will improve patient outcomes
and enable more efficient use of resources. Currently,
hospital admission and discharge planning are often
poorlyorganizedand inconsistently implemented, indicating
a need for closer relationships between all those involved in
patient care (Recommendation 1).
Improve patient education and support
Better education and support for individuals with
heart failure, and their families and caregivers, are
essential to improve outcomes and patients’ experi-
ence of care. Patients frequently lack the knowledge,
confidence, and support to be actively involved in
their own care, and their adherence to measures
important for long-term health is often poor (Recom-
mendation 2).
Provide equity of care for all patients
All patients should have timely access to an appropriate
range of diagnostic procedures, therapies, and long-term
follow-up care. Currently, the quality of care varies
considerably among hospitals, and across regions and
countries (Recommendation 3).
Figure 9 Healthcare experience for patients with acute heart failure, depending on symptoms at presentation. Patient experience also
varies across countries and regions, depending on service provision. aPossible future provision. HF, heart failure.
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Treatment of acute heart failure
Key points
Importance of timely and appropriate
treatment
Rapid treatment in the acute care setting is the second
step in the management of patients with acute heart fail-
ure. However, effective treatment of patients with acute
heart failure remains a challenge.
Outcomes for patients with acute heart failure have
shown only modest improvements over the past two
decades, death rates remain high, and patients experience
frequent hospital readmissions. The options for treating
acute heart failure have generally changed little over this
time. In contrast, for patients in the stable, chronic phase
of the disease, the introduction of new treatments and
therapeutic approaches has been accompanied by con-
siderable reductions in death and ill health.15 Two ap-
proaches are therefore needed to improve the treatment
of patients with acute heart failure:
• the development of new treatment options; and
• better use of patient management strategies and
existing therapies.
While research efforts continue into the development of
new, more effective therapies for acute heart failure,
making better use of the currently available treatments,
management strategies and resources should substantially
improve the outcomes and quality of care for patients with
acute heart failure.
The first part of this section considers the available
treatment options for acute heart failure and the chal-
lenges of developing new therapies. The second part looks
at how organization and delivery of inpatient care can af-
fect patient outcomes. The transition to long-term care af-
ter stabilization of an acute heart failure episode is
covered in the next section.
Current approaches to the treatment of
acute heart failure
Diuretics, vasodilators, and inotropic agents form the basis
of acute heart failure treatment, and current approaches
using these three main types of drug are summarized
below. More detailed evaluations of the therapeutic
options for acute heart failure are provided by a number
of treatment guidelines, including those from the ESC,15
ACCF/AHA,17 Canadian Cardiovascular Society,91 and
HFSA,19 but are beyond the scope of this report.
Diuretics promote the production of urine and increase
water excretion. They are the mainstay of treatment, as the
majority of patients hospitalized with acute heart failure
have lung congestion and/or swollen legs or ankles (periph-
eral oedema) and so require the removal of excess fluid to
relieve symptoms. Treatment guidelines recommend intrave-
nous administration of diuretics, as absorption following oral
dosing can vary substantially among patients.15,17,19 Therapy
leads to rapid relief of breathlessness in the majority of
patients, and individuals should be monitored regularly to
assess the efficacy and safety of treatment.15,17,19
Increased doses or addition of a second diuretic may be
needed for some patients, if symptoms persist. Careful
monitoring is required to avoid excessive reductions in
fluid volume, which could lead to low blood pressure
and/or affect kidney function, and/or result in low potas-
sium levels, which could increase the risk of heart rhythm
disorders.15,17,19
Vasodilators act to widen blood vessels and can be added
to diuretic therapy to reduce the build-up of fluid in the tis-
sues and lungs in acute heart failure; they should be avoided
in patients with low blood pressure.15,17,19 These agents can
reduce pressure in the circulatory system, whichmay relieve
breathlessness and congestion. Carefulmonitoring is needed
to avoid low blood pressure and reduced blood flow to the
organs, which may affect kidney function.15,19
Inotropic agents act directly on the heart muscle to
increase the force of contraction. They can increase the
volume of blood pumped by the heart, raise blood
pressure, and improve the flow of blood to the tissues;
however, their use in acute heart failure is limited because
of concerns over potential adverse effects. Guidelines
therefore recommend that inotropic agents should be
used only for critically ill patients in whom low blood
• Symptom relief is the first priority in the treatment of
acute heart failure. Available treatments are effective
for many patients but have changed little over the past
two decades.
• More research is needed to identify new treatments for
acute heart failure, but clinical research in the emer-
gency setting is challenging.
• The quality of acute heart failure care varies consi-
derably among hospitals, regions, and countries, as
shown by differences in death rates and hospital
performance measures.
• Patients’ prospects are improved when experts in heart
failure are responsible for or involved in their care.
• Socio-economically deprived, disadvantaged, and older
patients are at a particularly high risk of developing
heart failure, and of dying as a result.
• Applying our knowledge of the best treatment practices
across all patients can provide better outcomes for
acute heart failure with currently available therapies.
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pressure and/or reduced cardiac output means that blood
flow to vital organs is compromised.15,17
The use of evidence-based cardiovascular medications
for chronic heart failure is important for the effective
long-term care of patients following an acute episode (see
section on Transition from Hospital to Community Care).
Barriers to the development of more
effective treatments
Effective clinical trials are key to the development of
new, evidence-based treatments for acute heart failure.
However, their design presents a number of challenges
in terms of patient enrolment, the timing of treatment
administration, and selection of appropriate measures
of success (‘outcome endpoints’).92
Trials assessing the effects of therapies on the symp-
toms of acute heart failure require early patient enrolment
and rapid treatment administration, within hours of
admission.92 Allowing later enrolment 1–2days after
admission means that early treatment effects cannot be
assessed and could also affect the characteristics of the
patient population. For example, many patients experi-
ence improvements in acute dyspnoea within 3–24h with
current therapies; the subsequent enrolment of symp-
tomatic patients could capture a disproportionately high
proportion of those with refractory symptoms and a
particularly poor prognosis.92 Patient enrolment in the
emergency department can, however, prove challenging.
Study protocols need to ensure that staff are available to
identify and enrol patients effectively, with careful con-
sideration given to obtaining informed consent, as this
may prove difficult in acutely ill patients.93
A wide range of outcome measures is potentially of
interest in acute heart failure, and care is needed to select
the most appropriate endpoints for the aims of the trial
(Figure 10).92 Death from cardiovascular causes or from
all causes offers the most rigorous endpoints, but it is not
knownwhether a short-term therapy for acute heart failure
would be capable of reducing long-term death rates (for ex-
ample, by preventing damage to heart muscle).92 Assess-
ment of symptoms such as breathlessness (dyspnoea) may
be an alternative endpoint; however, the ability to detect
changes in dyspnoea depends on how it is measured and
on variations in patient disease characteristics.92 There is
therefore a lack of consensus on the most effective assess-
ment measures to use in clinical trials.92
The heterogeneity of patients with acute heart failure pre-
sents another challenge, as patients with different symptoms
and underlying causes may respond very differently to a par-
ticular therapy. Classifying individuals according to present-
ing symptoms, type of cardiac dysfunction (i.e. reduced or
preserved ejection fraction), and underlying cardiac cause
would provide a better-defined patient population.94 Particu-
lar therapies could then be assessed in the subpopulations
most likely to benefit from a given treatment approach.
Despite the challenges of clinical research in acute
heart failure, new medications are being developed.
Determining whether promising results in early clinical
trials translate into reduced death rates during acute
decompensation or in the subsequent chronic phase of
treatment will require additional larger-scale studies.
New or improved medicines for acute heart failure would
have the greatest impact in the context of high standards
of care. It is also important that access to newly licensed
medications is not limited, so that their introduction can
benefit the maximum number of patients.
Tools for improved medical
decision-making in acute heart failure
Several factors affecting outcomes, including kidney
function, SBP, age, and ischaemia, have been identified
in patients with acute heart failure.95 This has led to
suggestions that these factors could be used to help direct
resources to those patients who need them most.
Studies have consistently shown that impaired kidney
function is significantly associated with increased long-
term death rates and more frequent readmission in
patients hospitalized with acute heart failure.40,96 Abnor-
mally high or low SBP at discharge was associated with
increased death rates at 1 year in the Canadian Enhanced
Feedback for Effective Cardiac Treatment Heart Failure
study.97 In the Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF), low SBP at admission was associated
with an increased death rate, both in hospital and follow-
ing discharge.98 In the same study, patients whose hospi-
talization was precipitated by poor blood flow to the heart
Figure 10 A range of potential endpoints for major clinical trials
in acute heart failure. Reproduced and adapted by permission of
the European Society of Cardiology from Zannad F et al.92
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(e.g. a heart attack) showed a significant increase in risk-
adjusted death rate.99
Although various factors are known to affect the
prognosis for individuals with acute heart failure, there
are no clear, established guidelines for assessing the like-
lihood of a patient having acute heart failure and for using
this to help to determine their care. The aim of this so-
called ‘risk stratification’ is to manage patients more effec-
tively, directing resources to those who need them most.
It could allow for the identification of low-risk patients
who present to the emergency department but who are
suitable for treatment in observation units or for early dis-
charge home, rather than being kept in hospital.100,101 Al-
ternatively, it could help to identify high-risk patients who
would benefit from a close follow-up after discharge.102
Several models for risk stratification have been pro-
posed, ranging from schemes based on a few assessments
(such as admission SBP and oxygen saturation,103 age and
renal function,104 or SBP and renal function105) to com-
plex models involving multiple factors.102,106 However,
none of these is sufficiently well developed for wide-
spread adoption, mainly because of the variation in pre-
sentation and underlying causes of acute heart failure.
The use of blood-based biomarkers to aid the diagnosis,
admission, discharge, and treatment management and to
reduce readmissions in acute heart failure is also being
investigated.
What is needed for more effective
in-hospital care?
The organization and delivery of in-hospital care has an
important effect on outcomes for patients treated for
acute heart failure. Adopting the most effective manage-
ment strategies across all patients should substantially
improve the outcomes and quality of acute heart failure
care. Teamwork between cardiologists and physicians
and nurses in other hospital departments (e.g. emergency,
internal medicine, intensive care) and outside hospital is
essential to improve outcomes and care quality.
Cardiologist vs. non-cardiologist care
The type of care (cardiologist or non-cardiologist) re-
ceived in hospital is associated with differences in the
outcomes for patients with acute heart failure. A national
audit of heart failure care in England and Wales showed
lower in-hospital death rates for patients treated on cardi-
ology wards (7.8%) than on general medical wards
(13.2%) or on other wards (17.4%).3 Findings were
similar for post-discharge death rates (Figure 11), and
the differences remained even after adjusting for possible
variation in patient characteristics. Studies of patients
hospitalized for heart failure in North America also
reported lower 30day107,108 and 1 year107,109 death rates
for those treated by cardiologists than for those treated
by other specialist healthcare professionals.
Differences in hospital care, discharge medications, and
follow-up recommendations have also been reported
across specialties. Patients were more likely to undergo di-
agnostic procedures such as echocardiography and exer-
cise testing when treated by a cardiologist rather than
by a non-cardiologist.107,109–111 Medications shown to be
effective in chronic heart failure were more likely to be
prescribed to cardiologist-treated patients at discharge
than to those cared for by other specialists.3,107,109,111 In-
creased use of medications at discharge was also reported
for patients treated in a heart failure unit.112 In England
and Wales, patients were more likely to receive specialist
follow-up by a cardiologist and/or in a heart failure clinic
if treated on a cardiology ward than if treated on other
wards.3 The establishment of a dedicated in-hospital
heart failure unit can also enhance outcomes in acute
heart failure, with marked reductions reported in avoid-
able readmissions for heart failure113 and in a composite
measure of readmission and death.112
Quality improvement programmes and care pathways
Quality improvement programmes have proved successful
in enhancing the level of care for patients with acute heart
failure. In OPTIMIZE-HF, hospitals were provided with a
variety of tools to improve heart failure management,
including best-practice treatment algorithms and discharge
checklists.114 Marked improvements in two performance
measures were observed over the 2year study period: the
issuing of complete discharge instructions (increased from
47% to 67%) and smoking cessation counselling (up from
48% to 76%). The use of medications for chronic heart fail-
ure at discharge either increased (from 76% to 86%) or was
Figure 11 Cardiology wards have better post-discharge survival
rates for patients with heart failure than general medical or other
wards. Reproduced with permission from National Institute for
Cardiovascular Outcomes Research (NICOR), University College
London, UK.3
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unchanged (at just over 80%), depending on drug class, in-
dicating that further efforts are needed to promote their
use. The use of specific process-of-care improvement tools
increased over time and was associated with lower in-
hospital and post-discharge 60–90day death and rehospi-
talization rates.114
The use of care pathways—systematic plans for the
care of particular patients over a particular time—has
been shown to improve outcomes in patients hospitalized
with acute heart failure. Studies have reported reductions
in readmission and in-hospital death rates and in the
length of hospital stay compared with usual care.115
Variations in the quality of acute heart
failure care
Equal access to high-quality care is essential in ensuring
the best outcomes for all patients with acute heart failure.
However, marked variations in the quality of care can be
seen in different hospitals.
Quality performance indicators for heart failure manage-
ment reveal substantial differences in care across hospitals.
Analysis of ADHERE data for patients with acute heart fail-
ure showed marked variations among hospitals in manage-
ment practices measured by four core care performance
indicators (known as HF-1 to HF-4) relating to good patient
communication and appropriate prescribing practice.116
Across different hospitals, the rate of compliance with the
practice defined by each performance measure varied
widely, from 70–95% in the most compliant hospitals to
0–70% in the least compliant (Figure 12). In addition, the
analysis showed marked differences among hospitals in
the length of hospital stay (ranging from 2.3 to 9.5days)
and in rates of death in hospital (ranging from 0% to
11.1%).116 Increasing compliance with these core care per-
formance indicators should therefore improve the overall
quality of care for patients.
An analysis of data from over 3000 hospitals in the USA
also reported wide variations in care quality across hospi-
tals, as measured by these four performance indicators, al-
though it improved over the 2 year study period.117 In
England and Wales, the National Heart Failure Audit
revealed considerable differences across hospitals in a
number of areas of heart failure care, including the
proportions of patients undergoing key diagnostic tests,
receiving cardiovascular medications on discharge, and
being referred to cardiology follow-up services.3
Differences in patient outcomes and the use of
healthcare resources also illustrate variations in heart
failure care among hospitals and across regions. Signifi-
cant regional differences in outcomes were seen for
patients hospitalized for acute heart failure in Canada,
with readmission rates and in-hospital death rates varying
across provinces (Figure 13).118 Wide variations in hospi-
tal performance have been reported for Medicare patients
hospitalized with a principal diagnosis of heart failure in
the USA.119 Rates were adjusted to take account of
different patient characteristics and ranged from 6.6% to
18.2% for in-hospital death and from 17.3% to 32.4% for
30day readmission. Substantial differences in death and
30day rehospitalization rates were also seen among
hospitals in Scotland for patients following their first
hospitalization for acute heart failure.120
Analysis of six teaching hospitals in California, USA,
revealed wide variations in death rates across the sites
for patients with heart failure, with 180day rates ranging
from 17.0% to 26.0% (when adjusted for differences in pa-
tient characteristics between hospitals).121 Days spent in
Figure 12 Compliance with core performance measures for heart failure varies widely among hospitals.116 The graph shows the
distribution of compliance rates across the 223 hospitals analysed. Hospitals were ranked according to compliance rate for each
measure, and values are shown for hospitals at the 10th (low compliance), 25th, 50th, 75th, and 90th (high compliance) percentiles
of the ranking distribution. aDischarge instructions or guidance. bLeft ventricular function documentation obtained or scheduled.
cSpecific medication prescribed at discharge for left ventricular systolic dysfunction, if indicated. dSmoking cessation counselling, if
indicated (n=220). LV, left ventricle.
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hospital and treatment costs also varied considerably over
the 180day period after initial hospitalization, with a two-
fold difference in the number of hospital days reported
across sites. There was an inverse correlation between pa-
tient outcome and use of hospital resources as measured
by treatment costs and days in hospital. Hospitals with
higher resource use had lower death rates, even after taking
into account the differences in patient characteristics.121
Patient perspective
It seems like a heart doctor will look at your heart
[but] if you have any other problems, the doctor will
just tell you to ‘go to that clinic, go to this clinic, go to
that clinic’.73
Impactof social factorson treatmentand
quality of care
The social make-up of patients with heart failure could
affect their management andmay contribute to the low pro-
file of the disease. Patients with heart failure are typically
elderly; in the USA, almost one in four patients diagnosed
with heart failure is aged 80years or above.14 Age at
first hospitalization for heart failure averages 70–
75years.5,6,9,10,40,53 Women comprise slightly more than
50% of patients with heart failure in the USA9,40,53 and
40–45%of patients in European studies5,10,45 and are on av-
erage about 5 years older than men at hospitalization.3,6,55
Age has several important implications for the man-
agement of patients with acute heart failure. Prescription
of medications according to treatment guidelines has been
shown to decrease with patient age,3 so the oldest patients
might not receive the most effective therapy. This is
compounded by the fact that older patients are likely to have
a complex disease with multiple co-morbidities, which may
limit the treatment options available. Furthermore, women
make up a greater proportion of the oldest patients6 and
are more likely to have heart failure with preserved ejection
fraction, for which the treatment options are limited.17
Heart failure is particularly common among socially
disadvantaged individuals. Studies have shown that lower
socio-economic status is independently associated with a
greater risk of developing heart failure and an increased
risk of readmission after hospitalization compared with
higher socio-economic status, even after adjusting for
other demographics and risk factors.122 Several other
studies have reported an increased risk of death with
lower socio-economic status,60,123–125 although one study
in England reported no such differences.56 Most evidence
suggests that medication use is not related to socio-
economic status, although data are limited and one study
has reported lower prescribing rates for some classes of
drug among more deprived patients.122
Socio-economic factors are likely to have a particular
impact on older women with heart failure.126 Data from
the USA show marked socio-economic disparities between
genders among older people, with more elderly women
than men living in poverty.126 Furthermore, more older
women than men live alone and may lack the social
and/or family support that is associated with better
outcomes in patients with heart failure.126 Women with
heart failure frequently report a lack of psychological
and social support in studies examining patient experi-
ences and perceptions of their illness.64
Need for better measures of care quality
Several performance measures are used to evaluate the
quality of hospital care for patients with heart failure. Each
measure defines a particular management practice, such as
prescription of a particular class of medication at discharge.
Differences in compliance with these measures among hos-
pitals are used as an indicator of variation in the quality of
care.117,127 For this approach to be valid, there should be a
close link between the individual measures and patient out-
comes, but evidence suggests that this is not the case for
many performance indicators.128–131
An analysis of over 5700 patients hospitalized for heart
failure showed that only one of the five measures of inpa-
tient care recommended by the ACCF/AHA was associated
with death or rehospitalization rate following discharge.128
Figure 13 Variation in readmission and in-hospital death rates
for acute heart failure across provinces in Canada.118 aAge and
sex adjusted.
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By contrast, a non-recommended measure (prescription of
antihypertensive medication for left ventricular systolic
function at discharge) was a predictor of both death and
death or rehospitalization during the 60 to 90day follow-
up period. Compliance with this measure was also associ-
ated with lower death rates over 1year of follow-up in a
larger study, whereas no associations were seen for the four
ACCF/AHA measures analysed.129 A study of more than
15000 patients hospitalized for heart failure showed that
socio-economic status and hospital characteristics, such as
its type and the number of heart failure admissions, were
stronger predictors of death and readmission rates in the
30days after discharge than hospital compliance with the
ACCF/AHA performance measures.130
Using current performance indicators to rank the quality
of care provided by hospitals also appears problematic. The
use of two different groups of measures showed little or no
correlation with 30day death rates or 30day readmission
rates, and most of the individual measures also showed no
correlation with outcomes.131 The ranking of individual
hospitals varied considerably according to which set of per-
formance or outcome measures was used.
Readmission within 30days of the initial hospitaliza-
tion for heart failure is also a focus of attention as a poten-
tial indicator of care quality.132,133 However, a study of
over 17000 patients with heart failure showed that
30day readmission was not associated with 30day death
rates: indeed, higher readmission rates were associated
with increased compliance with other performance
measures.132 Other studies have shown reductions in
death rates even when rehospitalization rates increased,
suggesting that rehospitalization alone is not a useful
measure of poor heart failure care.52,134,135 Furthermore,
the imposition of financial penalties for 30day read-
missions, as in the USA,136 could discourage appropriate
in-hospital treatment of a patient during an acute episode.
The problems with existing performance measures
indicate a need for new metrics to assess the quality of
care for patients hospitalized with heart failure. To be
effective, these measures should cover hospital care and
the transition to community care and show a clear link
with patient outcomes or improved efficiency.127 Perfor-
mance measures will also need to take into account
factors such as the severity of illness and socio-economic
status in order to provide an accurate picture of the differ-
ences in care quality among hospitals.
Our evidence-based policy
recommendations
Provide equity of care for all patients
All patients should have timely access to an appropriate
range of diagnostic procedures, therapies, and long-term
follow-up care. Currently, the quality of care varies con-
siderably among hospitals, and across regions and coun-
tries (Recommendation 3).
Appoint experts to lead heart failure care across
disciplines
A multidisciplinary team led by a heart failure expert
should oversee the care of patients with acute heart
failure and the development of protocols, training,
and local auditing to make excellent care the norm
(Recommendation 4).
Stimulate research into new therapies
Increased funding is needed for research into new and
more effective therapies, medical devices, and care strate-
gies for acute heart failure. New approaches are urgently
required to address unmet needs (Recommendation 5).
Develop and implement better measures of care
quality
Performance measures based on robust, evidence-based
clinical recommendations should be developed and used
to improve the quality of care for patients with acute heart
failure. Current performance measures are variable and
lack an evidence base, and their use may have unintended
consequences (Recommendation 6).
Transition from hospital to community
care
Key points
• Patients with acute heart failure who have been
stabilized in hospital need effective long-term care to
reduce the likelihood of another episode.
• The major unmet need for managing acute heart
failure is to enable rapid discharge from hospital while
preventing recurrent admission and death.
• The use of evidence-based medications, in line with
treatment guidelines, is important to the success of
long-term care.
• Self-care reduces patients’ risks of rehospitalization
and death, and it comprises self-maintenance, self-
monitoring, and self-management.
• Education and support for patients, their families, and
their caregivers are required to ensure that patient self-
care is effective.
• The value of palliative and end-of-life care should be
communicated more widely and sooner to patients
and their families, to encourage discussion and timely
decision-making.
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Importance of effective long-term care
Effective long-term care is essential for good outcomes for
patients following an episode of acute heart failure. The
challenge is to ensure a seamless transition from inpatient
to outpatient care for all patients, and integration with
chronic heart failure management.
Several factors are important to ensure continuity of
care for these patients, including the following:
• an effective disease management programme
• use of evidence-based treatments
• adoption of patient self-management behaviours
• effective education and support for patients, families,
and caregivers
The first part of this section examines the transition to
long-term care; the second part considers the role of pal-
liative care services in the management of patients with
heart failure.
Disease management programmes and
multidisciplinary teams
Discharge from hospital and the transition to outpatient
care and follow-up is an important stage in the manage-
ment of patients with acute heart failure. The goal is to pro-
vide a high-quality transition to outpatient care and ensure
integration with chronic care services. Disease manage-
ment programmes have been developed as a tool to facili-
tate the transition process. These typically include in-
hospital patient education and multiple follow-up visits,
although the length and intensity of the programmes can
vary considerably.137 The components recommended by
the ESC guidelines are shown in Table 4.15
Numerous studies have demonstrated the benefits of dis-
ease management programmes on patient outcomes, with
reported reductions in rates of readmission138–140 and
death after discharge,140 and improvements in quality of
life,138,139 compared with usual care. Although the types
of intervention differ across studies, with not all studies
showing improved outcomes,137 simple approaches such
as early patient follow-up have been shown to be effec-
tive.141 Nurse-led transitional care has been well studied
and can prove effective.138 Programmes involving patient
and family/caregiver education, home visits, and regular
telephone support have been shown to reduce readmission
and death rates, and to improve quality of life.134,142 Patient
education is another important component of disease
management programmes. In France, the national educa-
tion programme for heart failure patients (Insuffisance
Cardiaque: Éducation Thérapeutique) has proved effective
in reducing deaths from all causes in patients with chronic
heart failure.143
Evidence suggests that the type of follow-up care can
also have an impact on outcomes for patients with heart
failure. Follow-up by cardiologists or specialist nurses
was associated with reduced death rates in England
and Wales.3 Studies have shown reductions in rates of
rehospitalization113,144,145 and death,135,144,146 and im-
provement in quality of life,145 during follow-up at a
specialist heart failure clinic compared with usual care.
Not all studies have reported benefits for heart failure
clinics. A study in Denmark reported similar rates of death
and hospital admission in patients with heart failure who
received extended follow-up care from a heart failure clinic
or from their own primary care physician.147 All patients
were, however, stabilized on optimal therapy and received
education in heart failure self-management before entering
the study, and the majority of patients in the primary care
physician group also received regular follow-up.147 This
suggests that the quality and level of care, rather than the
location, are important for good outcomes.
Evidence-based medications improve
long-term outcomes
The introduction of new treatments and therapeutic
approaches has improved outcomes for patients in the
stable, chronic phase of heart failure. It is therefore
important that all patients receive these medications
following stabilization of acute heart failure.
Large randomized controlled clinical trials have
shown reductions in death and ill health for patients
with stable heart failure and reduced left ventricular
Table 4 Components of heart failure management prog-
rammes recommended by the European Society of Cardiology
guidelines
Optimized medical and device management
Adequate patient education, with special emphasis on adherence
and self-care
Patient involvement in symptom monitoring and flexible diuretic
use
Follow-up after discharge (regular clinic and/or home-based visits;
possibly telephone support or remote monitoring)
Increased access to health care (through in-person follow-up and
by telephone contact; possibly through remote monitoring)
Facilitated access to care during episodes of decompensation
Assessment of (and appropriate intervention in response to) an
unexplained increase in weight, nutritional status, functional
status, quality of life, and laboratory findings
Access to advanced treatment options
Provision of psychosocial support to patients and family and/or
caregivers
Professional bodies in North America17,19,91 and Australasia18,195
have also published guidelines. Reproduced by permission of the
ESC from McMurray et al.15
Improving care in acute heart failure 131
© 2015 Oxford PharmaGenesis Ltd ESC Heart Failure 2014; 1: 110–145
DOI: 10.1002/ehf2.12021
ejection fraction with a range of medications that act on
the cardiovascular system.15 Implanted pacemaker and
defibrillation devices have also proved effective for some
types of patient.15 These benefits have translated into
everyday clinical practice: registry and community-based
studies show improved outcomes for patients with
chronic heart failure associated with increasing use of
evidence-based treatments.
Hospitalization rates for patients with chronic heart
failure decreased with greater compliance with guidelines
for the use of appropriate heart and blood pressure
medication in the Medical Management of Chronic Heart
Failure in Europe and Its Related Costs survey, conducted
in six European countries.148 Patients who were pre-
scribed all three medications in line with the guidelines
(complete guideline compliance) had lower hospitaliza-
tion rates for heart failure and for any cardiovascular
problem during the 6month follow-up than those re-
ceiving fewer medications (moderate or low guideline
compliance) (Figure 14).148
In a German registry study, marked reductions in 1 year
and 3 year death rates coincided with an increase in the
proportion of patients who received all three recom-
mended heart and blood pressure medications according
to treatment guidelines.149 The death rate was lowest
among patients with high adherence, highlighting the im-
portance of interventions to increase the implementation
of treatment guidelines among healthcare professionals.
Patients with heart failure typically experience several
acute episodes interspersed with periods of stable, chronic
disease (see Figure 5). Following an acute episode, it is
therefore important to ensure that all patients receive
and continue to receive the medications known to be
effective in chronic heart failure. Halting or slowing the
progression of the disease is important, as most deaths
due to heart failure occur during episodes of acute decom-
pensation, for which very few new evidence-based medi-
cines have been developed in the past 20–30 years.
Programmes to improve discharge and
transition to follow-up care
Evidence shows that disease management programmes
can improve the quality of care and outcomes in patients
with acute heart failure. However, in one survey, only 7
of 26 European countries reported that heart failure
management programmes were being used in more than
30% of hospitals.150 Even when programmes are in place,
they are often underused; a survey in Canada showed that
only 15% of patients hospitalized for heart failure were
referred to a specialist heart failure clinic for follow-
up.151 Furthermore, a Web-based survey reported wide
variations in the implementation of key practices by
hospitals enrolled in a quality improvement initiative to
reduce preventable patient readmissions after hospitaliza-
tion for heart failure or a heart attack.152 About 15% of
hospitals employed all four discharge and follow-up prac-
tices, and only 5% had all three medication management
practices in place. There are therefore grounds for opti-
mism that redesign of the processes for treatment of heart
failure and their widespread implementation will allow
reduction of death and disease due to heart failure.
Use of technology in heart failure
management
The increased use of technology for monitoring patients
with heart failure following discharge may help to
improve outcomes and prevent future acute episodes,
although results from studies have been mixed.153 One
telemonitoring approach involves automated transmis-
sion of patient-measured weight, blood pressure, heart
rate, and heart rhythm data to the medical centre. In
one study, death rates after 1 year were lower among
patients receiving telemonitoring (29%) or regular
telephone support from a nurse (27%) compared with
usual care (45%).154 In contrast, a later study revealed
no differences in death rate between the telemonitoring
and usual-care groups over 12–28months’ follow-up.155
However, this study involved stable, lower-risk patients
who were already well managed, suggesting that there
was little opportunity for telemonitoring to provide
additional benefits over usual care.
More research is needed into the development and use
of telemonitoring systems. A study of blood pressure
Figure 14 Compliance with treatment guidelines reduced the
need for hospitalization in a large European study.148 Compli-
ance with guidelines for the use of three treatments: complete,
all three treatments; moderate, two treatments; low, no or one
treatment.
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monitoring via an implanted wireless device for up to
15months showed that hospital admissions for heart
failure and the length of stay were reduced compared
with usual care, as a result of more adjustments to medi-
cations.156 Use of an automated telephone-based interac-
tive voice response system did not, however, lead to
differences in death or readmission rates compared with
usual care over 6months’ follow-up in another study.157
Monitoring of fluid accumulation via an implanted device
is another approach but requires further development
for routine daily use.158 A survey of heart failure clinics
in the Netherlands showed that telemonitoring did not
deliver the anticipated benefits in terms of patient care,
reduced workload, or lower treatment costs,159 suggest-
ing that attention should also be paid to how systems
are implemented.
Technology offers other opportunities to help pa-
tients and healthcare professionals improve heart
failure management. Interactive Internet-based educa-
tion programmes may help patients with self-care,
while online groups are a useful source of support for
patients and their families. The use of telemonitoring
to supervise and monitor patients remotely during
exercise (telerehabilitation) could help to increase
physical activity among patients with heart failure,160
while online consultations making use of video links
and digital stethoscopes could reduce the need for
face-to-face consultations.161
Crucial role of patient self-care
The patient plays a key role in the long-term manage-
ment of heart failure after hospitalization for an acute
episode.162 Even with frequent contact with healthcare
professionals, the active involvement of patients (sup-
ported by family, friends, and/or caregivers) in the man-
agement of their disease is important in ensuring good
outcomes. Three different components make up patient
self-care: maintenance, monitoring, and management
(Figure 15).163 Maintenance involves adherence to med-
ication and lifestyle changes, while monitoring of the
signs and symptoms of heart failure includes activities
such as daily weighing to assess fluid retention. Self-
care management means responding appropriately to
any changes in symptoms—for example, by increasing
the dose of medications prescribed for use as needed.
Effect of medication adherence on treatment
outcomes
Ensuring that patients take their prescribed medications
for heart failure improves outcomes. In the Candesartan
in Heart Failure—Assessment of Reduction in Mortality
and Morbidity studies in patients with heart failure, good
adherence to prescribed medications was associated with
lower death rates from all causes than was poor adher-
ence.164 Poor treatment adherence has also been linked
to exacerbation of heart failure, with increased rates of
hospitalization and emergency department visits.165–167
Nevertheless, wide variations in adherence to cardio-
vascular medications have been reported for patients with
heart failure, with rates ranging from 10% to 96%
depending on how adherence was measured and
defined.168,169 A study of patients after hospitalization
for heart failure showed that, among patients prescribed
a medication at discharge, only 80% were adherent to
medication after 1month.170 Adherence was approxi-
mately 60–65% between 3months and 1 year after
discharge.
Clear, easy-to-follow instructions about medication use
are important for patient adherence. Of patients newly
discharged home following hospitalization for heart
failure, only 34% were taking all medications as pre-
scribed shortly after discharge, despite written discharge
instructions.171 A lack of understanding of the discharge
instructions and confusion about apparently conflicting
instructions between the discharging physician and the
primary care physician were the main reasons for non-
adherence. Many patients also continued to take their
previous medications, even though they were no longer
prescribed.171
Symptom monitoring and management
Routine monitoring of the signs and symptoms of heart
failure is important for early detection and management
of any deterioration in the disease. Adherence to daily
weight monitoring has been linked to a reduced risk of
emergency department visits and hospitalizations for
heart failure.172 Despite this, daily weighing to monitor
changes in fluid retention is reported by fewer than half
of all patients173 and is even uncommon among
individuals newly discharged from hospital following
an acute episode.171,174 Furthermore, many patients do
not recognize changes in weight as a potentially impor-
tant indicator of clinical deterioration.175 In one study,
31% of patients newly discharged after heart failureFigure 15 The three components of patient self-care.163
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hospitalization could not name any symptom of
worsening heart failure.171 The limited ability of pa-
tients with heart failure to recognize changes in their
condition contributes to the often long delays seen
between developing symptoms and seeking medical
attention.84
Responding appropriately to changes in heart failure
signs and symptoms is an important part of effective
patient self-care.162 By initiating treatment strategies in
response to changing symptoms—for example, by re-
ducing fluid intake or increasing the dose of diuretic in
response to fluid retention—and monitoring their effects,
patients can play an active role in the management of
their disease. Improved education and support are needed
so that patients feel willing and able to participate fully in
self-care behaviours.
Patient perspectives
I could make neither head nor tail of it, because in the
hospital they had other names for the same tablets.
I have so many tablets, well, I have to take 500mL
water with the medication. But that is no ‘tasty
drink’, so I take the tablets and hop [makes a drinking
gesture], so I don’t count that. [patient with severe
heart failure who was prescribed a fluid restriction
of 1500mL].176
Exercise and other lifestyle changes
Regular exercise has been linked to reductions in hos-
pitalizations for heart failure and improvements in
survival time.162 Furthermore, physical activity can pro-
vide valuable improvements in exercise duration, lung
function, and blood flow in patients with stable heart
failure and may improve patients’ quality of life and
reduce depression and anxiety.162 In Heart Failure: a
Controlled Trial Investigating Outcomes of Exercise
Training (HF-ACTION), involving over 2300 patients
with stable heart failure, exercise training was safe,
led to improved quality of life, and was associated with
a lower combined rate of death and hospitalization
(adjusted for differences in patients’ disease character-
istics and prognosis), compared with usual care.177
The study also suggests that exercise training may be
as effective as cardiovascular medication in improving
outcomes for patients with heart failure.177–179
Despite the benefits of regular exercise and recommen-
dations for exercise training or regular physical activity in
the latest treatment guidelines,15,17 few patients with
heart failure report taking regular exercise.180,181 Over
50% of patients in one study reported doing no physical
activity.175 Maintaining adherence to exercise pro-
grammes is also a challenge. In HF-ACTION, weekly exer-
cise decreased over time, with only 30% of patients
achieving the target level at the end of the 3 year study.177
Several other lifestyle changes are also recommended
for patients with heart failure, including smoking cessa-
tion, limited alcohol consumption, and restricted dietary
sodium and fluid intake.162 However, adherence to these
recommendations is often poor.180,181
Patient perspective
They keep saying, you got to lose this weight, here’s
the stuff you should and shouldn’t eat, and all that.
If I’m sitting here more or less 24hours a day, 7 days
a week in front of this TV… [I] can’t lose weight just
by not eating a potato chip or something like this.
It’s impossible… And I can’t breathe even if I did
exercise… Ten years—I know I’m overweight. I don’t
need them to tell me that. But there’s not too much
a person can do about it just by eating rice or card-
board… It just—it’s frustrating.73
Partner perspective
I like to stay fit, keep exercising. Swinging [sic],
cycling, and walking. But he doesn’t, he thinks it’s
not important. Not necessary. And I’ve given it a rest.
He knows it is important for cardiac patients, but it’s
not in his nature.182
Selective adherence to self-care recommendations
Large variations in adherence to different self-
management behaviours have been observed among
individuals with heart failure.180,181 In a worldwide study,
most patients reported taking their medication as pre-
scribed, but exercise levels were typically low, with over
50% of individuals not engaging in regular exercise in
16 of the 21 patient populations studied.181
Large variations in adherence to self-management
behaviours were also reported in a study of patients with
heart failure in the USA, even though individuals received
self-care education at regular clinic visits (Figure 16).180
Only 9% of patients showed good adherence to all eight
behaviours. Good adherence was associated with fewer
hospital admissions, fewer days in hospital and reduced
emergency department visits, and better health status
compared with poor adherence in this study.180
Supportive role of family and friends
Support from family and friends (social support) can
have beneficial effects for patients with heart failure. It
has been linked to improved quality of life and re-
ductions in hospitalizations and can promote self-
management behaviours in patients.183 Higher levels of
social support are associated with increased medication
adherence184,185 and improved dietary adherence185 in
patients with heart failure.
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The quality of support provided by family and/or friends
is important. Self-care was significantly better among pa-
tients with heart failure who had a high level of support
from their partner than in those who received moderate
levels of support or did not have a partner.186 High levels
of social support had significant beneficial effects on a num-
ber of behaviours, including medication adherence, regular
exercise, fluid restriction, and seeking medical attention for
weight gain. However, no differences in self-care behav-
iours were observed between patients receiving moderate
support and those with no partner.186
The family may also have a negative influence on
patient self-management. In a survey, one in four patients
regularly missed self-management behaviours because of
the influence of family,187 suggesting a need for more
effective ways of involving family and friends in the care
of patients with heart failure.
Social support is important to improve the care of
patients with heart failure, but the burden it places on
caregivers can affect them physically, emotionally, and
financially.66,188 Almost one in three partners of patients
with heart failure experienced a moderate level of care-
giver burden, and higher caregiver burden was linked to
poorer mental and physical health in caregivers.189 Family
caregivers reported that patient care had a marked impact
on their daily schedule, so that activities seemed centred
around providing care.190 Caregiving limited social
activities in particular and negatively affected caregivers’
ability to cope with stress and their emotional and finan-
cial well-being.191 However, some caregivers experienced
positive feelings from the responsibilities and rewards of
caring for a family member.66,188
Caregivers reported receiving a lack of social and
emotional support themselves, as well as the need for
more information and advice on caring for patients.190
Furthermore, low levels of perceived social support
increased the burden felt by caregivers, suggesting that
caregivers would benefit from improved education and
support.190
Partner perspective
He comes first, but it isn’t easy for me either, I don’t
mean to complain but if you are used to going out
and now you have to stay home all the time, you
know all the time. My daughter lives around the cor-
ner and I go out a lot with her, with the dog, to keep
my mind off things… I dare not stay away much lon-
ger. My daughter wants me to come along to go to
the seaside and we will also take the dog with us,
but I am afraid to go. To go out for a whole day is
much too long.182
Appropriate palliative and end-of-life
care
The aim of palliative care is to improve the quality of life for
patients facing life-threatening illness and their families.192
It is therefore surprising that limited use is made of special-
ist palliative care services in heart failure, given the serious-
ness of the disease and its high death rate. In England and
Wales, only 3.1% of patients were referred to palliative care
services in 2012 following their first admission for acute
heart failure, with 7.3% of patients being referred after re-
admission.3 There is therefore a clear need to increase
awareness about, and improve access to, palliative care ser-
vices for individuals with heart failure.193
Palliative care services take a broad approach to disease
management, addressing the psychological, social, and
spiritual needs of patients and their families, in addition
to other aspects of care such as pain and symptom man-
agement. Palliative care can also play an important role
in discussions about the likely course of the disease and
wishes regarding end-of-life care.
A review of end-of-life care conversations revealed that
the majority of patients with heart failure did not feel they
had discussed the subject with their healthcare profes-
sional.194 Studies revealed an unwillingness on the part of
both healthcare professionals and patients to initiate conver-
sations about end-of-life care.194 A broader approach to pa-
tient management involving palliative care could improve
communicationwith patients and their families, increase un-
derstanding of the disease, and aid decision-making.
For palliative care to be most effective for individuals
with heart failure, it should be available throughout the
course of the disease, and not just considered in the termi-
nal stages.193 Such an approach would, however, require
its integration into disease management programmes
and involve effective coordination among healthcare pro-
fessionals involved in palliative care and in the
management of patients with heart failure.
Figure 16 Large variations in good adherence to self-care behav-
iours among patients with heart failure.180 Good adherence was
defined as patients reporting adherence to a given behaviour
‘all of the time’ or ‘most of the time’ over the past 4weeks.
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Patient perspective
A year ago, I was in the hospital… for 3weeks, and I
was told by one of the cardiologists I was seeing that
I should make plans and arrangements [such as]
looking for a nursing home, drawing up a will. I think
he was really worried about me at that time. At the
time, I was sort of shocked. I didn’t know what to
say. I came home after 3weeks in the hospital, and I
was really sort of afraid to do anything.73
Our evidence-based policy
recommendations
Optimize care transitions
Better integration of hospital care, community care, and
the emergency services will improve patient outcomes
and enable more efficient use of resources. Currently,
hospital admission and discharge planning are often
poorly organized and inconsistently implemented, indi-
cating a need for closer relationships among all those
involved in patient care (Recommendation 1).
Improve patient education and support
Better education and support for individuals with heart
failure, and their families and caregivers, are essential to
improve outcomes and patients’ experience of care.
Patients frequently lack the knowledge, confidence, and
support to be actively involved in their own care, and their
adherence to measures important for long-term health is
often poor (Recommendation 2).
Provide equity of care for all patients
All patients should have timely access to an appropriate
range of diagnostic procedures, therapies, and long-term
follow-up care. Currently, the quality of care varies con-
siderably among hospitals, and across regions and coun-
tries (Recommendation 3).
Improve end-of-life care
Effective approaches to palliative and end-of-life care,
addressing emotional and physical well-being, need to
be made an integral part of the care of patients with heart
failure, both in hospital and in the community (Recom-
mendation 7).
Promote acute heart failure prevention
Country-wide efforts to decrease risk factors for heart
failure, including high blood pressure and coronary
artery disease, should be intensified. Once heart failure
develops, progression of the disease should be prevented
or slowed by ensuring that appropriate evidence-based
care is implemented promptly (Recommendation 8).
Recommendations for wider
implementation
This report promotes eight policy recommendations based
on the evidence presented in the sections Clinical Course
of Acute Heart Failure, Diagnosis of Acute Heart Failure,
Treatment of Acute Heart Failure, and Transition from Hos-
pital to Community Care. Not only policy-makers but also
healthcare professionals, professional associations, organi-
zations that fund healthcare, industry, the public, care-
givers, and patients themselves have a role to play in
improving care in acute heart failure.
This section highlights opportunities for other stake-
holders to implement changes that will benefit patients
with acute heart failure, grouped under the heading of
each policy recommendation.
Optimize care transitions
More effective coordination and communication between
healthcare professionals would help to simplify the complex
trajectories that patients follow through the healthcare sys-
tem. Patient pathways vary according to the symptoms at
presentation, the underlying disease processes, the suitability
of particular short- and long-term treatments, and the pres-
ence of other medical conditions. Effective mechanisms
should be put in place for sharing information between dif-
ferent specialties and centres to enable patients to be closely
followed during hospitalization and after discharge.
Effective disease management programmes should im-
prove patient outcomes. They should include pre-
discharge education, post-discharge treatment optimiza-
tion, and long-term patient monitoring and should
connect to outpatient services for chronic heart failure
care, as well as taking account of coexisting illnesses.
Use of such disease management programmes should be
audited to improve compliance with recommendations.
Clear information for patients and caregivers about the
organization and provision of care should be available to
help them navigate the healthcare system.
Improve patient education and support
Active involvement of patients with heart failure and their care-
givers in the management of the disease should be
encouraged. Engagement in the daily monitoring of their
condition will enable patients to recognize changes in signs
and symptoms and to respond appropriately (e.g. by increas-
ingmedication dose or seekingmedical attention as needed).
Teaching of self-care behaviours, such as symptom monitor-
ing, treatment adherence, and regular exercise, is important
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for patients’ long-termhealth. Familymembers should also be
able to recognize and act on changes in symptoms.
Good communication between healthcare professionals
and patients should include discussions to identify
treatment goals and the needs and concerns of the patient
and their family and/or caregivers. Where possible, patients
should have an identified individual they can contact.
Increased research and development is needed to deter-
mine the most effective approaches to potentially helpful
new technologies, such as telemonitoring.
Provide equity of care for all patients
Management protocols need to be in place so that the best
practice is followed across all centres, ensuring high-
quality care for all, irrespective of age or economic status.
Appropriate diagnostic procedures, including echocar-
diography and blood biomarker tests, should be available
to all patients, and not just in hospital.
More flexible care options, better tailored to patient
needs, would help to increase the range of manage-
ment strategies available for patients with acute heart
failure—many of whom are admitted to hospital in
the absence of other suitable alternatives.
Appoint experts to lead heart failure
care across disciplines
Advocacy by healthcare professionalswith expertise in heart
failure is required to make sure that excellent care be-
comes the norm across hospitals, and education is needed
so that patients and public can recognize ‘good care’.
Stimulate research into new therapies
Improved patient management and better targeting of
existing treatments offer the promise of immediate bene-
fit to patients. Ensuring that the best management strate-
gies are in place will create an environment in which new
treatments can have the most impact on patient outcomes.
Develop and implement bettermeasures
of care quality
Reassessment of reimbursement systems would remove
perverse incentives that damage patient care. It is impor-
tant to reduce preventable admissions for heart failure,
but a financial penalty for 30day readmission may dis-
courage the appropriate in-hospital treatment of a patient
during an acute episode.
Optimaldistributionofhealthcareresourceswouldhelptoen-
sureadequateprovisionforanincreasednumberofpatients.
Quality improvement programmes and improved perfor-
mance measures would enable delivery of better care to
patients. Effective and efficient alternatives to hospitaliza-
tion (where appropriate) could provide more appropriate,
cost-effective options for patients.
Improve end-of-life care
End-of-life care protocols should be in place to ensure that
issues are raised by the healthcare team at the appropriate
time and that these involve family members and care-
givers as well as the patient.
Suitable communication skills training should be given
to healthcare professionals and other specialists, where
appropriate.
Promote acute heart failure prevention
Education programmes for the general public should raise
awareness of risk factors for heart failure, symptoms of
the disease, and actions that can help to prevent it.
Education for healthcare professionals should extend to
primary care physicians, nurses, pharmacists, and ambu-
lance staff.
More research is needed into the effects on heart failure
prevention of treating other medical conditions that
increase the risk of heart failure (or are underlying factors
in its development).
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ADHERE Acute Decompensated Heart Failure
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Emergency
ECG Electrocardiogram
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ESC-HF European Society of Cardiology–Heart
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FINN-AKVA Finnish Acute Heart Failure Study
HF Heart failure
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Investigating Outcomes of Exercise Training
HF-PEF Heart failure with preserved ejection
fraction
HF-REF Heart failure with reduced ejection
fraction
HFSA Heart Failure Society of America
HSCIC Health and Social Care Information
Centre
IABP Intra-aortic balloon pump
IN-HF Italian Registry on Heart Failure
LV Left ventricle
NDCHealth National Data Corporation Health
NICOR National Institute for Cardiovascular
Outcomes Research
NHFA National Heart Foundation of Australia
NIV Non-invasive ventilation
NP Natriuretic peptide
OFICA Observatoire Français de l’Insuffisance
Cardiaque Aiguë
OPTIMIZE-HF Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients with
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PaO2 Partial pressure of oxygen in arterial blood
SBP Systolic blood pressure
SpO2 Oxygen saturation of arterial blood
measured by pulse oximetry
VA Veterans Affairs
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